Zobrazeno 1 - 5
of 5
pro vyhledávání: '"E. R. Machulaitene"'
Publikováno v:
Онкогематология, Vol 0, Iss 1, Pp 21-28 (2022)
Peripheral neuropathy is one of the most common complications of Bortezomib treatment. In this article you can find a brief literature review and single center experience: we estimated the prevalence of neuropathy development and it’s characteristi
Externí odkaz:
https://doaj.org/article/2fe1fc5297b94a8cb1ce434af387a255
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 40-45 (2022)
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 6
Externí odkaz:
https://doaj.org/article/b683f210247445cdb987afa77e18fa09
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 6-13 (2022)
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate
Externí odkaz:
https://doaj.org/article/c2efdc3ba2154cfb809d445aa9adf43d
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 0, Iss 2, Pp 60-63 (2017)
The authors describe the clinical observation of a case of the aggressive systemic mastocytosis with skin involvement, the type of generalized urticaria pigmentosa. They also present literature data concerning the etiology, pathogenesis, diagnosis an
Externí odkaz:
https://doaj.org/article/67482a088a0f4d84948ce0d6d86aa452
Autor:
S. S. Bessmeltsev, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina
Publikováno v:
Онкогематология, Vol 7, Iss 1, Pp 6-14 (2014)
We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the over
Externí odkaz:
https://doaj.org/article/e2a2f3e21b514fa3bcb826edeb7fa3e9